Atrial fibrillation (AF) is the commonest rhythm disorder. The prevalence increases with age from less than 1 in 1000 in under 35s to over 100 in 1000 in people age 85 and over 1 . AF is an independent risk factor for thromboembolic stroke 2 and heart failure 3 and is associated with increased morbidity and mortality 4 . The risk of thromboembolism can be reduced by anti-platelet 5 or anticoagulation 6 therapy.
Uncertainty remains around whether control of ventricular rate or conversion to sinus rhythm is the most appropriate treatment strategy for AF. In the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study, a large randomised controlled trial involving over 4000 patients with AF and other risk factors for stroke or death, mortality rates were similar in those treated with rate or rhythm control therapy and side effects were higher in the rhythm-control group 7 .
NICE guidelines on the management of AF published in 2006 suggests rhythm control is preferable to rate control in the following patient groups with persistent AF 27 : Amiodarone is a class III anitarrhythmic drug 8 which acts by blocking sodium, potassium and calcium channels on cardiac myocytes to increase the refractory period of the cardiac action potential which can result in a longer QT interval being seen on electrocardiogram. It also has some class II activity by non-competitive B blockade 9 .
Amiodarone may also prevent electrical remodelling which can result from atrial overactivity 10 . Amiodarone has a number of significant adverse effects which can limit its use including pro-arrhythmic effects, thyroid disease, hepatotoxicity, pulmonary toxicity and ophthalmological disorders.
Flecainide is a class 1c anti-arrhythmic 8 . It acts by blocking sodium channels to reduce intracardiac conduction 11 . It has been associated with fatal arrhythmias in patients with structural heart disease.
Sotalol is a non-selective β blocker which also has class III anti-arrhythmic action 8 . It leads to an increase in duration of the cardiac action potential and slows repolarisation 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 giving rise to a prolongation of the QT interval on ECG which may predispose to ventricular arrhythmias 12 .
In this article we present a study using data from the General Practice Research Database (GPRD) evaluating the adverse events and predictors of treatment discontinuation in patients using these commonly prescribed anti-arrhythmic agents.
Methods
We conducted a retrospective case control note review and outcome linkage analysis on the GPRD routine clinical dataset to evaluate the adverse events and predictors of treatment discontinuation in patients using licensed rhythm modifying medication (amiodarone, flecainide and sotalol).
Population for Analysis
The GPRD collects data from over 350 practices in the UK. More than three million patients are currently contributing data and the system has over 35 million patient years on record making it the largest primary care routine patient record database in the world. Information including patients demographics, diagnoses, prescribing history and test results are collected using VISION software and collated centrally.
The GPRD has been widely used for pharmacoepidemiological research and data is quality assured by checks for consistency and completeness of data recording and adherence to GPRD guidelines 13 . 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 were included in the study if they had a first prescription of rhythm modifying medication, namely amiodarone, flecainide or sotalol, at least 12 months after the start of GPRD data collection and a second prescription of the same drug within six months of the first. Follow-up of these patients began on the date of the second prescription, representing chronic rhythm medication users. Each amiodarone, flecainide and sotalol user was matched to three control patients by age (within 2 years), gender, practice and calendar time. Eligible controls had at least 12 months data prior to the start date. Patients with a record of AF or "non-specific heart rhythm disorders" were excluded as controls.
Analysis
We evaluated the occurrence of known adverse events associated with amiodarone, flecainide and sotalol in patients on treatment compared with controls. For amiodarone we included hyperthyroidism and hypothyroidism, acute and chronic liver failure, pulmonary toxicity (pneumonitis or interstitial/alveolar pneumonitis), visual impairment (including blurred vision, visual halos, optic neuropathy or optic neuritis), congestive heart failure and all cause mortality. In the flecainide group we included acute and chronic liver disease, congestive heart failure and death. In the sotalol group we included hyperthyroidism and hypothyroidism, acute and chronic liver failure, congestive heart failure and all cause mortality.
The follow-up of all three groups was divided into current and past use. The periods of current use included the time from the date of a prescription for amiodarone, daily dose and number of tablets) plus an offset period. The period of offset was 2 months for amiodarone and 1 month for sotalol or flecainide to take into account their different half lives. The period of past use was from the expected end of treatment plus the offset period until the end of the GPRD data collection or patients death, whichever came first. Patients taking amiodarone, flecainide or sotalol were censored if they switched treatment to another antiarrhythmic.
Statistical Methods
We used Poisson regression to compare current users of amiodarone, flecainide and sotalol with past users and controls. Potential confounders included in the regression model were age, gender, body mass index, smoking history, alcohol use, history of ischaemic heart disease, heart failure, hypertension, cerebrovascular disease, diabetes mellitus, hyperthyroidism, prior drug use of statins, angiotensin receptor blockers and oral glucocorticoids, number of GP visits prior in the six to twelve months prior to index date and the socio-economic class of the practice region.
Data Mining Exercise
We also conducted a data mining sensitivity analysis to explore any differences in symptoms between those who stopped and those who continued treatment with amiodarone, flecainide or sotalol. Each patient who discontinued treatment was matched by age (within 5 years), gender and duration of treatment (<1 year, 1-3 years 3+ years) to one patient who continued treatment with the same drug. The symptoms recorded between the last prescription and time of treatment discontinuation were evaluated in patients who stopped treatment. A period of similar length was also 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 As shown in table 2, congestive heart failure was more common in past users of amiodarone than controls. Risk was increased further in current users of amiodarone compared with controls. Risk of hyperthyroidism was increased more than 10 fold in past amiodarone users and more than 20 fold for current users. Hypothyroidism was also significantly more common in past users and higher still in current users. There were only a small number of cases of liver failure so further meaningful statistical analysis was not possible. Pulmonary toxicity was more common in past users and current users but this was not statistically significant. Visual impairment was not significantly different between exposed and unexposed groups either for past users of amiodarone nor current users. All-cause mortality was significantly higher in current amiodarone users than controls. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Adverse Outcomes Related to Flecainide Use
Congestive heart failure was more common in past users of flecainide compared with controls but not statistically significantly different in current users. All-cause mortality was increased three-fold in current users of flecainide compared with the unexposed group. The number of cases of liver failure was small so statistical evaluation was not possible.
Excluding patients with an index date prior to 1996 did not alter these findings.
Adverse Outcomes Related to Sotalol Use
Congestive heart failure was more common in current users than controls and risk increased further for past users. All cause mortality was increased more than two-fold in the sotalol group. Hyperthyroidism was increased in current users and increased further in past users compared with controls. The risk of hypothyroidism was slightly increased in current users and further increased in past users of sotalol. The number of cases of liver failure was too small for analysis. There was no significant difference in pulmonary toxicity between exposed and unexposed groups for both past or current users. 
Results

Conclusions
Summary of main findings
Adverse events are much more common in patients currently or previously taking antiarrhythmics than age and gender matched controls, especially for amiodarone users. In patients with atrial fibrillation, all three antiarrhythmics were associated with increased all-cause mortality. Congestive heart failure was more common in all amiodarone and sotalol users as well as past users of flecainide. Thyroid disease was more common in patients treated with amiodarone and sotalol but only amiodarone had an increased risk of pulmonary toxicity. The number of patients with liver failure was too small in all cases for statistical analysis. The adverse events arising in patients treated with amiodarone, flecainide and sotalol were similar to the reasons given for discontinuation of treatment in the data mining exercise.
Congestive heart failure is a risk factor for AF 11 so this association in all groups was not surprising. Also, some guidelines suggest rhythm rather than rate-control is the preferred treatment for congestive heart failure further explaining the increased risk seen in patients taking rhythm-control agents compared to control 27 . Amiodarone has a causal link with thyroid disease and pulmonary toxicity however a causal association between sotalol and thyroid disease has not previously been well recognised. β blockers are used to manage patients with hyperthyroidism which may explain this association although the reason for an increased incidence of hypothyroidism in patients taking sotalol is less clear.
Strengths and limitations of the study
The GPRD is a large well-validated database containing information on patients from wide demographic backgrounds. The system allows complex analyses of adverse events recorded in patients with atrial fibrillation and receiving anti-arrhythmic medications.
The criterion for diagnosis of AF was unclear and may have been on clinical grounds, by electrocardiogram or by a specialist but this is impossible to elucidate from the GPRD system. There may also be a significant time interval between the time data was recorded to the time of this study and clinical practice may have changed during The study compared patients with atrial fibrillation taking antiarrhythmic medications with controls who both did not have AF and were not taking antiarrhythmic medications. There is a well recognised excess mortality in all patients with AF 4 which may explain some of this result, furthermore, patients treated with rhythm rather than rate control may have worse prognosis disease. However, at least some of this effect could also be due to malignant side effects of anti-arrhythmic medications.
The number of patients with liver failure was too small for meaningful analysis however it may have been interesting to examine the liver function tests in cases and controls to see if there was a difference between the two groups.
Comparison with existing literature
Amiodarone
Proarrhythmic effects
Prolongation of the QT interval in patients taking amiodarone can predispose to torsade de pointes (TdP), polymorphic ventricular fibrillation, which can be fatal. The incidence of TdP in patients prescribed amiodarone is however less than 1% 14 . The risk of TdP is increased in the presence of electrolyte abnormalities or concurrent proarrhythmogenic medications 15 . The most common arrhythmia associated with amiodarone use is bradycardia which can be profound in older patients with a history of ischaemic heart disease and may require pacing 16 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Amiodarone is associated with thyroid disorders which can range from subclinical abnormalities found on thyroid function tests to clinically apparent hypo-and hyperthyroidism 17 . Hypothyroidism is more common in women and patients with antithyroid antibodies 18 , however, in a sub-study of the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) involving mostly male patients with an average age of 67 years, subclinical hypothyroidism was seen in 25.8% of patients treated with amiodarone compared with 6.6% of controls (p<0.0001) and clinically significant hypothyroidism was found in 5.0% of amiodarone treated patients compared with 0.3% of controls (p<0.001). There was no statistically significant difference in hyperthyroidism in this subgroup between amiodarone-treated patients and controls 19 however, elsewhere estimates of hyperthyroidism range from 1 to 23% in patients taking amiodarone 20 .
Hepatotoxicity
Elevated liver enzymes are seen in 15-30% of patients taking amiodarone and annual incidence of hepatitis and cirrhosis is 0.6% 21 . This is more common in patients on high doses of amiodarone but has been reported in those receiving low dose oral therapy 22 .
Pulmonary toxicity
Amiodarone pulmonary toxicity (APT) is estimated to occur in 5-7% of patients receiving amiodarone. Mortality is approximately 5-10% 23 . It is most common amongst patients undergoing cardiac surgery who are receiving high doses of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 amiodarone to prevent ventricular arrhythmia however APT has also been seen in patients following lower doses of oral treatment 24 .
Ophthalmological Disorders
Corneal deposits are seen in up to 100% of patients receiving amiodarone. These rarely impair vision. Optic neuritis has also been associated with amiodarone therapy although a causal link is not certain 25 . This occurs in less than 1% of patients and routine retinal screening has not been shown to be beneficial 26 .
Amiodarone is recommended in the National Institute of Health and Clinical Excellence (NICE) guidelines for use in atrial fibrillation only after failure of other treatments 27 and is most commonly initiated by a specialist. 
Flecainide
Flecainide was found to increase mortality in patients with a history of myocardial infarction and assymptomatic or mild ventricular arrhythmias in the Cardiac Arrhythmia Suppression Trial (CAST) study 29 . As a result of these findings, flecainide is contraindicated in patients with structural heart disease. The drug does 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 however have a role as "pill-in-the-pocket" therapy for those with known paroxysmal AF. In this approach to treatment, patients with at least one episode of previously documented AF carry a single dose of flecainide with them and take the medication at the onset of symptoms. A study of 165 patients with a total of 618 AF episodes presenting with sudden onset of palpitations without haemodynamic compromise (systolic BP 100 or more and mean heart rate of greater than 70) found that 94% of episodes were terminated by flecainide within a mean time of 113 minutes. Side effects were infrequent with one episode of rapid atrial flutter and 11 cases of noncardiac side effects including nausea, vertigo and asthenia 30 .
Flecainide is also indicated for rhythm control in persistent AF in patients with a structurally normal heart 27 . A systematic review, which included 5 trials involving flecainide following cardioversion, found a reduction in recurrence rate of AF. There was however an increase in withdrawal of treatment in the flecainide groups compared with control due to side effects including proarrhythmic events 31 .
Flecainide can be fatal in overdose, due to widening of the QRS complex and prolongation of the PR interval seen on ECG predisposing to ventricular tachycardia or bradycardic episodes requiring pacing 32 33 .
Sotalol
In the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T), amiodarone and sotalol were found to have equivalent efficacy for conversion to sinus rhythm (27. 1% v 24.2%, p=0.45) but amiodarone was superior in maintaining sinus rhythm (median time to recurrence of AF 487 days v 74 days, p<0.001) except in patients 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 with ischaemic heart disease where both drugs were equivalent. Sotalol was more efficacious than placebo in all groups 34 .
The main cardiovascular side effect of sotalol relates to prolongation of the QT interval which can predispose to torsade de pointes 35 . In a systematic review of 9 studies comparing sotalol with control, there was an increased risk of proarrhythmic events in the sotalol groups (OR 2.20, 95% CI 1.31-3.69) 31 .
In a substudy of the AFFIRM trial, adverse events causing discontinuation of treatment in the 135 patients in the sotalol arm included congestive heart failure (2.2%), bradycardia (2.2%), gastrointestinal events (4.4%), pulmonary events (0.7%) and syncope (0.7%) 36 . Another study investigating long term efficacy and safety of sotalol in 106 patients found 22% had tolerable side effects such as gastrointestinal discomfort (2%), neurological disturbance (11%), assymptomatic bradycardia (7%) and general weakness (2%). A further 10% discontinued treatment due to significant adverse effects, 4% of these were due to proarrhythmic events and the remainder were due to assymptomatic QT prolongation, congestive heart failure, symptomatic bradycardia and gastrointestinal events.
Adverse events associated with antiarrhythmic agents are commonly described in the literature as discussed above, however, they continue to be commonly prescribed. A Canadian study looking at drug use in 465 patients with new onset AF found that 36.4% (92/253) of patients taking sotalol and 64.1% (25/39) of patients taking amiodarone had contraindications or warnings. The number of patients taking flecainide was small but 33% (2/6) patients also had contraindications or warnings 37 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Implications for future research and practice
Atrial fibrillation is increasingly common as the population ages and survival from ischaemic heart disease improves. AF guidelines recommend rhythm-control agents for younger patients, those who are symptomatic, present for the first time with lone AF or have congestive heart failure 27 . However, the AFFIRM study found no mortality benefit from rhythm control compared to rate control and a higher rate of adverse events in patients taking rhythm control agents. Further research is required to establish the benefit-risk ratio of rhythm-control treatments in the subgroups of patients recommended to receive these agents. Patients with atrial fibrillation should be carefully counselled about potential adverse effects before starting rhythm-control agents both to allow informed consent and ensure symptoms of adverse events are recognised and reported by the patient early to allow discontinuation or change of treatment as required.
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Aim
To assess the risk of adverse events in patients with AF receiving rhythm control agents.
Design of study
Retrospective case control note review and outcome linkage analysis.
Setting
Patients with a diagnosis of AF receiving amiodarone, flecainide or sotalol in practices registered with the General Practice Research Database (GPRD) in the UK. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Method
Retrospective case control note review and outcome linkage analysis on the GPRD routine clinical dataset to evaluate the adverse events and predictors of treatment discontinuation in patients using licensed rhythm modifying medication.
Results
Adverse events are more common in patients currently or previously taking amiodarone, flecainide or sotalol than age and gender matched controls. All three antiarrhythmics were associated with increased all-cause mortality. Congestive heart failure was more common in all amiodarone and sotalol users as well as past users of flecainide. Thyroid disease was more common in patients treated with amiodarone
Introduction
Atrial fibrillation (AF) is the commonest rhythm disorder. The prevalence increases with age from less than 1 in 1000 in under 35s to over 100 in 1000 in people age 85 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1 . AF is an independent risk factor for thromboembolic stroke 2 and heart failure 3 and is associated with increased morbidity and mortality 4 . The risk of thromboembolism can be reduced by anti-platelet 5 or anticoagulation 6 therapy.
NICE guidelines on the management of AF published in 2006 suggests rhythm control is preferable to rate control in the following patient groups with persistent AF 27 :
• Symptomatic Amiodarone is a class III anitarrhythmic drug 8 which acts by blocking sodium, potassium and calcium channels on cardiac myocytes to increase the refractory period of the cardiac action potential which can result in a longer QT interval being seen on 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Amiodarone may also prevent electrical remodelling which can result from atrial overactivity 10 . Amiodarone has a number of significant adverse effects which can limit its use including pro-arrhythmic effects, thyroid disease, hepatotoxicity, pulmonary toxicity and ophthalmological disorders.
Sotalol is a non-selective β blocker which also has class III anti-arrhythmic action 8 . It leads to an increase in duration of the cardiac action potential and slows repolarisation giving rise to a prolongation of the QT interval on ECG which may predispose to ventricular arrhythmias 12 .
Methods
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Data Mining Exercise
We also conducted a data mining sensitivity analysis to explore any differences in symptoms between those who stopped and those who continued treatment with amiodarone, flecainide or sotalol. Each patient who discontinued treatment was 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 As shown in table 2, congestive heart failure was more common in past users of amiodarone than controls. Risk was increased further in current users of amiodarone compared with controls. Risk of hyperthyroidism was increased more than 10 fold in past amiodarone users and more than 20 fold for current users. Hypothyroidism was also significantly more common in past users and higher still in current users. There were only a small number of cases of liver failure so further meaningful statistical analysis was not possible. Pulmonary toxicity was more common in past users and current users but this was not statistically significant. Visual impairment was not significantly different between exposed and unexposed groups either for past users of amiodarone nor current users. All-cause mortality was significantly higher in current amiodarone users than controls.
Results were not affected by excluding patients with an index date prior to 1996.
Adverse Outcomes Related to Flecainide Use
Congestive heart failure was more common in past users of flecainide compared with controls but not statistically significantly different in current users. All-cause mortality was increased three-fold in current users of flecainide compared with the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Excluding patients with an index date prior to 1996 did not alter these findings.
Adverse Outcomes Related to Sotalol Use
Congestive heart failure was more common in current users than controls and risk increased further for past users. All cause mortality was increased more than two-fold in the sotalol group. Hyperthyroidism was increased in current users and increased further in past users compared with controls. The risk of hypothyroidism was slightly increased in current users and further increased in past users of sotalol. The number of cases of liver failure was too small for analysis. There was no significant difference in pulmonary toxicity between exposed and unexposed groups for both past or current users.
Results were not affected by excluding patients with an index date prior to 1996. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Conclusions
Summary of main findings
Adverse events are much more common in patients currently or previously taking antiarrhythmics than age and gender matched controls, especially for amiodarone users. In patients with atrial fibrillation, all three antiarrhythmics were associated with increased all-cause mortality. Congestive heart failure was more common in all amiodarone and sotalol users as well as past users of flecainide. Thyroid disease was more common in patients treated with amiodarone and sotalol but only amiodarone had an increased risk of pulmonary toxicity. The number of patients with liver failure was too small in all cases for statistical analysis.
The adverse events arising in patients treated with amiodarone, flecainide and sotalol were similar to the reasons given for discontinuation of treatment in the data mining exercise.
Congestive heart failure is a risk factor for AF 11 so this association in the amiodarone and sotalol groups was not surprising. Also, some guidelines suggest rhythm rather 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 27 . Flecainide is contraindicated in patients with structural or functional heart disease and there was no significant difference in heart failure between cases and controls in current flecainide users. Amiodarone has a causal link with thyroid disease and pulmonary toxicity however a causal association between sotalol and thyroid disease has not previously been well recognised. β blockers are used to manage patients with hyperthyroidism which may explain this association although the reason for an increased incidence of hypothyroidism in patients taking sotalol is less clear.
Strengths and limitations of the study
The criterion for diagnosis of AF was unclear and may have been on clinical grounds, by electrocardiogram or by a specialist but this is impossible to elucidate from the GPRD system. There may also be a significant time interval between the time data was recorded to the time of this study and clinical practice may have changed during this period, however, analysis excluding data prior to 1996 did not significantly alter the results.
The study compared patients with atrial fibrillation taking antiarrhythmic medications with controls who both did not have AF and were not taking antiarrhythmic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 which may explain some of this result, furthermore, patients treated with rhythm rather than rate control may have worse prognosis disease. However, at least some of this effect could also be due to malignant side effects of anti-arrhythmic medications.
Comparison with existing literature
The study showed a significantly higher rate of adverse events in patients taking rhythm control agents compared with controls. The side effect profile of antiarrhythmic agents, particularly amiodarone, has been well described in existing literature.
Amiodarone
Proarrhythmic effects
Prolongation of the QT interval in patients taking amiodarone can predispose to torsade de pointes (TdP), polymorphic ventricular fibrillation, which can be fatal. The incidence of TdP in patients prescribed amiodarone is however less than 1% 14 . The risk of TdP is increased in the presence of electrolyte abnormalities or concurrent proarrhythmogenic medications 15 . The most common arrhythmia associated with amiodarone use is bradycardia which can be profound in older patients with a history of ischaemic heart disease and may require pacing 16 . Arrhythmic events could partly explain the excess mortality in patients receiving amiodarone. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 in patients taking amiodarone 20 . In this study, patients receiving amiodarone were twenty times more likely to have hyperthyroidism than controls.
Hepatotoxicity
The cases of liver failure were small in number in this study precluding meaningful statistical analysis however other studies have shown that elevated liver enzymes are seen in 15-30% of patients taking amiodarone and annual incidence of hepatitis and cirrhosis is around 0.6% 21 . This is more common in patients on high doses of amiodarone but has been reported in those receiving low dose oral therapy 22 .
Pulmonary toxicity
Deleted: E 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Amiodarone pulmonary toxicity (APT) is estimated to occur in 5-7% of patients receiving amiodarone. Mortality is approximately 5-10% 23 . It is most common amongst patients undergoing cardiac surgery who are receiving high doses of amiodarone to prevent ventricular arrhythmia however APT has also been seen in patients following lower doses of oral treatment 24 .
Ophthalmological Disorders
Corneal deposits are seen in up to 100% of patients receiving amiodarone. These rarely impair vision. Optic neuritis has also been associated with amiodarone therapy although a causal link is not certain 25 . This occurs in less than 1% of patients and routine retinal screening has not been shown to be beneficial 26 . This is consistent with the findings of this study which did not show a significant difference in visual impairment between those receiving amiodarone and controls. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Flecainide
Flecainide was found to increase mortality in patients with a history of myocardial infarction and assymptomatic or mild ventricular arrhythmias in the Cardiac Arrhythmia Suppression Trial (CAST) study 29 . As a result of these findings, flecainide is contraindicated in patients with structural heart disease in clinical practice. The drug does however have a role as "pill-in-the-pocket" therapy for those with known paroxysmal AF. In this approach to treatment, patients with at least one episode of previously documented AF carry a single dose of flecainide with them and take the medication at the onset of symptoms. A study of 165 patients with a total of 618 AF episodes presenting with sudden onset of palpitations without haemodynamic compromise (systolic BP 100 or more and mean heart rate of greater than 70) found that 94% of episodes were terminated by flecainide within a mean time of 113 minutes. Side effects were infrequent with one episode of rapid atrial flutter and 11 cases of non-cardiac side effects including nausea, vertigo and asthenia 30 .
Flecainide can be fatal in overdose, due to widening of the QRS complex and prolongation of the PR interval seen on ECG predisposing to ventricular tachycardia or bradycardic episodes requiring pacing 32 33 . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Sotalol
In the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T), amiodarone and sotalol were found to have equivalent efficacy for conversion to sinus rhythm (27. 1% v 24.2%, p=0.45) but amiodarone was superior in maintaining sinus rhythm (median time to recurrence of AF 487 days v 74 days, p<0.001) except in patients with ischaemic heart disease where both drugs were equivalent. Sotalol was more efficacious than placebo in all groups 34 .
The main cardiovascular side effect of sotalol relates to prolongation of the QT interval which can predispose to torsade de pointes 35 . In a systematic review of 9 studies comparing sotalol with control, there was an increased risk of proarrhythmic events in the sotalol groups (OR 2.20, 95% CI 1.31-3.69) 31 . This could partly explain the excess mortality seen in patients receiving sotalol in the study.
In a substudy of the AFFIRM trial, adverse events causing discontinuation of treatment in the 135 patients in the sotalol arm included congestive heart failure (2.2%), bradycardia (2.2%), gastrointestinal events (4.4%), pulmonary events (0.7%) and syncope (0.7%) 36 . Another study investigating long term efficacy and safety of sotalol in 106 patients found 22% had tolerable side effects such as gastrointestinal discomfort (2%), neurological disturbance (11%), assymptomatic bradycardia (7%) and general weakness (2%). A further 10% discontinued treatment due to significant adverse effects, 4% of these were due to proarrhythmic events and the remainder were due to assymptomatic QT prolongation, congestive heart failure, symptomatic bradycardia and gastrointestinal events. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Adverse events associated with antiarrhythmic agents are commonly described in the literature as discussed above, however, they continue to be commonly prescribed. A Canadian study looking at drug use in 465 patients with new onset AF found that 36 .4% (92/253) of patients taking sotalol and 64.1% (25/39) of patients taking amiodarone had contraindications or warnings. The number of patients taking flecainide was small but 33% (2/6) patients also had contraindications or warnings 37 .
Implications for future research and practice
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